About CNS therapeutics

CNS therapeutics cater to CNS disorders that affect the structure or function of the brain or spinal cord such as Parkinson’s disease, epilepsy, Alzheimer’s disease, anxiety, depression, and bipolar disorders.
Technavio’s analysts forecast the Global CNS therapeutics market to grow at a CAGR of 4.36% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the CNS therapeutics market. To calculate the market size, the report considers the revenue generated from the sales of therapeutics for CNS disorders.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global CNS Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Eli Lilly
• F. Hoffmann-La Roche
• Johnson & Johnson
• Merck
• Novartis

Market driver
• Increasing prevalence of mental illness
• For a full, detailed list, view our report

Market challenge
• Side effects of CNS therapeutics
• For a full, detailed list, view our report

Market trend
• Increased adoption of new-generation drugs
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.